(Q36938416)

English

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression

scientific article published on 30 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Philip T Ninan

4

0 references

author name string

Gabor I Keitner

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Steven J Garlow

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Christine E Ryan

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

David A Solomon

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Charles B Nemeroff

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Martin B Keller

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

30 June 2008

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Psychiatric Research

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

43

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

205-214

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Realistic expectations and a disease management model for depressed patients with persistent symptoms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Use of atypical antipsychotics in refractory depression and anxiety.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Issues in treatment-resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Pharmacologic management of difficult-to-treat depression in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Toward rapproachment in the placebo control debate. A calculated compromise of power

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

A rating scale for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Recognizing and meeting the needs of patients with mood disorders and comorbid medical illness: a consensus conference of the Depression and Bipolar Support Alliance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Diagnosis and definition of treatment-resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Managing treatment-resistant major depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

The definition and meaning of treatment-resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

Definition and epidemiology of treatment-resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

29 September 2017

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

27 June 2018

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

27 June 2018

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

27 June 2018

Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

27 June 2018

Reboxetine adjunct for partial or nonresponders to antidepressant treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

27 June 2018

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

4 September 2018

Relationships among measures of treatment outcome in depressed patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

4 September 2018

Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

4 September 2018

Which depressed patients respond to nefazodone and when?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

4 September 2018

A novel augmentation strategy for treating resistant major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

4 September 2018

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3685867

4 September 2018

"Difficult-to-treat depression"

1 reference

https://pubmed.ncbi.nlm.nih.gov/18586273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Undertreatment of major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18586273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

https://pubmed.ncbi.nlm.nih.gov/18586273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JPSYCHIRES.2008.05.003

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36938416&oldid=1566647057"